GLP‐1 Medications in Obesity Care

In partnership with

GLP‑1 medications — once used primarily for diabetes — are now at the center of a global conversation about obesity treatment. The World Health Organization has released its first formal guidelines recommending these drugs as part of a comprehensive weight‑management plan.

Pelosi Made 178% While Your 401(k) Crashed

Nancy Pelosi: Up 178% on TEM options
Marjorie Taylor Greene: Up 134% on PLTR
Cleo Fields: Up 138% on IREN

Meanwhile, retail investors got crushed on CNBC's "expert" picks.

The uncomfortable truth: Politicians don't just make laws. They make fortunes.

AltIndex reports every single Congress filing without fail and updates their data constantly.

Then their AI factors those Congress trades into the AI stock ratings on the AltIndex app.

We’ve partnered with AltIndex to get our readers free access to their app for a limited time.

Congress filed 7,810 new stock buys this year as of July.

Don’t miss out on direct access to their playbooks!

Get Congress Trade Updates

_{Past performance does not guarantee future results. Investing involves risk including possible loss of principal.}

The guidance reflects mounting evidence that GLP‑1 medications can support significant weight loss while improving metabolic health. They work by slowing digestion, reducing appetite, and helping regulate blood sugar levels.

However, the WHO emphasizes that medication alone is not a magic solution. Lifestyle changes, including nutrition and physical activity, remain essential. The organization also highlights the need for equitable access, noting that cost and availability remain major barriers in many regions.

As demand for GLP‑1 drugs continues to surge, the new guidelines are expected to influence healthcare policy, insurance coverage, and clinical practice worldwide.